In recent years, the treatment of advanced tumors, especially metastatic melanoma, has been revolutionized by the use of immune checkpoint inhibitors (ICIs), including PD-1/PD-L1 inhibitors and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Here, PDCD1 is linked to metastatic melanoma.